Literature DB >> 1691125

Prospective randomised trial of laser therapy only and laser therapy followed by endoscopic intubation for the palliation of malignant dysphagia.

H Barr1, N Krasner, A Raouf, R J Walker.   

Abstract

Forty six consecutive patients admitted for the relief of malignant dysphagia were prospectively randomised to receive laser therapy only or initial laser therapy followed by endoscopic intubation. Twenty patients were treated in each group with six exclusions. The patients' swallowing ability was assessed before and during the remainder of their life on a 0-4 scale with 0 being normal swallowing and 4 total dysphagia. The patient's quality of life was measured at the same times, using a physician's assessment (QL index) and the patient's own assessment using a linear analogue self assessment (LASA). There was a significant correlation between all the QL index and the LASA scores collected (n = 126; rs = 0.594, p less than 0.001). The mean monthly dysphagia grade correlated with the QL index (rs = 0.433, p less than 0.001) and the LASA (rs = 0.272, p less than 0.002). There was no significant difference in the dysphagia grade before or after treatment in either group. Dysphagia fluctuated more in those treated with the laser only, however, than in those with a tube inserted. There was also no significant difference in the quality of life measured between the two groups of patients. The complication rate (laser only 10%, laser/intubation 40%, p less than 0.05) was significantly higher in intubated patients. The recurrent dysphagia rate (laser only 25%, laser/intubation 45%, NS) was higher in patients treated with intubation, but they required fewer endoscopic procedures. Overall both procedures were effective in relieving dysphagia and in maintaining quality of life. There was no procedure related mortality in either group.

Entities:  

Mesh:

Year:  1990        PMID: 1691125      PMCID: PMC1378261          DOI: 10.1136/gut.31.3.252

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  Intracavitary irradiation in palliation of carcinoma of oesophagus and cardia.

Authors:  C G Rowland; K M Pagliero
Journal:  Lancet       Date:  1985-11-02       Impact factor: 79.321

2.  Endoscopic laser palliation for advanced malignant dysphagia.

Authors:  S G Bown; R Hawes; K Matthewson; C P Swain; H Barr; P B Boulos; C G Clark
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

Review 3.  Upper intestinal and biliary tract endoprosthesis.

Authors:  G N Tytgat; J F Bartelsman; F C Den Hartog Jager; K Huibregtse; E M Mathus-Vliegen
Journal:  Dig Dis Sci       Date:  1986-09       Impact factor: 3.199

4.  Palliative laser therapy for malignant dysphagia.

Authors:  N Krasner; H Barr; C Skidmore; A I Morris
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

5.  Massive pneumoperitoneum following laser therapy of inoperable oesophageal carcinoma.

Authors:  P T Brooks; A C Troop; H Barr; N Krasner
Journal:  Clin Radiol       Date:  1988-05       Impact factor: 2.350

6.  Oesophagogastrectomy in the treatment of malignancy of the thoracic oesophagus and cardia.

Authors:  J N Leverment; D M Milne
Journal:  Br J Surg       Date:  1974-09       Impact factor: 6.939

7.  Intubation of gastro-oesophageal malignancies: a survey of current practice in Britain, 1980.

Authors:  J R Bennett
Journal:  Gut       Date:  1981-04       Impact factor: 23.059

8.  The insertion of oesophagogastric tubes in malignant oesophageal strictures: endoscopy or surgery?

Authors:  A H Lishman; A W Dellipiani; H B Devlin
Journal:  Br J Surg       Date:  1980-04       Impact factor: 6.939

9.  Evaluation of quality of life in patients receiving treatment for advanced breast cancer.

Authors:  T J Priestman; M Baum
Journal:  Lancet       Date:  1976-04-24       Impact factor: 79.321

10.  Tube introducer and modified Celestin tube for use in palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy.

Authors:  M Atkinson; R Ferguson; G C Parker
Journal:  Gut       Date:  1978-07       Impact factor: 23.059

View more
  19 in total

1.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  W H Allum; S M Griffin; A Watson; D Colin-Jones
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

Review 2.  Palliation in oesophageal neoplasia.

Authors:  J Bancewicz
Journal:  Ann R Coll Surg Engl       Date:  1999-11       Impact factor: 1.891

3.  Palliation for esophageal and cardial cancer.

Authors:  J Payne-James; D Loft; G Misiewicz; D Silk
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

4.  Palliation of malignant dysphagia.

Authors:  J Payne-James; J J Misiewicz; D Silk
Journal:  Gut       Date:  1990-10       Impact factor: 23.059

5.  Palliation of oesophageal cancer--endoscopic intubation and laser therapy.

Authors:  J D Urschel; J S Cockburn; A V Foote
Journal:  Postgrad Med J       Date:  1991-05       Impact factor: 2.401

Review 6.  General surgery.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

7.  Laser and brachytherapy in the palliation of adenocarcinoma of the oesophagus and cardia.

Authors:  G M Spencer; S M Thorpe; I R Sargeant; G M Blackman; J Solano; J S Tobias; S G Bown
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

8.  A randomized comparison of dilatation alone versus dilatation plus laser in patients receiving chemotherapy and external beam radiation for esophageal carcinoma.

Authors:  B S Anand; Z A Saeed; P A Michaletz; C B Winchester; M A Doherty; J H Liem; D Y Graham
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

9.  Palliation of malignant dysphagia using the Nd:YAG laser.

Authors:  R Carter; J S Smith; J R Anderson
Journal:  World J Surg       Date:  1993 Sep-Oct       Impact factor: 3.352

Review 10.  Quality of life with carcinoma of the esophagus.

Authors:  G A Gelfand; R J Finley
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.